Aeglea Bio Therapeutics Inc (AGLE) stock is down -55.44% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives AGLE stock a score of 27 out of a possible 100. That rank is chiefly influenced by a short-term technical score of 1. AGLE's rank also includes a long-term technical score of 1. The fundamental score for AGLE is 78. In addition to the average rating from Wall Street analysts, AGLE stock has a mean target price of $13.25. This means analysts expect the stock to gain 272.19% over the next 12 months.
AGLE has an Overall Score of 27. Find out what this means to you and get the rest of the rankings on AGLE!
